Dornase alfa

From Wikipedia, the free encyclopedia
(Redirected from Pulmozyme)

Template:Short description Template:Cs1 config Template:Medref Template:Short description Page Template:Infobox drug/styles.css has no content.

Page Module:Infobox/styles.css has no content.

Dornase alfa
Clinical data
Trade namesPulmozyme
AHFS/Drugs.comMonograph
MedlinePlusa694002
License dataPage Template:Plainlist/styles.css has no content.
Pregnancy
category		Page Template:Plainlist/styles.css has no content.
Routes of
administration		Inhalation
ATC codePage Template:Plainlist/styles.css has no content.
Legal status
Legal statusPage Template:Plainlist/styles.css has no content.
Identifiers
CAS NumberPage Template:Plainlist/styles.css has no content.
PubChem CIDPage Template:Plainlist/styles.css has no content.
PubChem SIDPage Template:Plainlist/styles.css has no content.
IUPHAR/BPSPage Template:Plainlist/styles.css has no content.
DrugBankPage Template:Plainlist/styles.css has no content.
ChemSpiderPage Template:Plainlist/styles.css has no content.
UNIIPage Template:Plainlist/styles.css has no content.
KEGGPage Template:Plainlist/styles.css has no content.
ChEBIPage Template:Plainlist/styles.css has no content.
ChEMBLPage Template:Plainlist/styles.css has no content.
NIAID ChemDBPage Template:Plainlist/styles.css has no content.
PDB ligandPage Template:Plainlist/styles.css has no content.
CompTox Dashboard (EPA)Page Template:Plainlist/styles.css has no content.
Chemical and physical data
FormulaC1321H1999N339O396S9
Molar mass29254.04 g·mol−1
3D model (JSmol)Page Template:Plainlist/styles.css has no content.
Data page
Template:Infobox drug/data page link
Page Template:Nobold/styles.css has no content. ☒NcheckY (what is this?)Page Template:Nobold/styles.css has no content.  (verify)

Dornase alfa, sold under the brand name Pulmozyme, is used for the treatment of cystic fibrosis.[3] It is a recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA.[3] Dornase alfa hydrolyzes the DNA present in sputum/mucus and reduces viscosity in the lungs, promoting improved clearance of secretions.[3] It is produced in Chinese hamster ovary cells.[3]

Medical uses

Dornase alfa is indicated for the management of people with cystic fibrosis to improve pulmonary function.[3]

A 2021 Cochrane systematic review found that dornase alfa probably improves lung function (FEV1) compared with placebo/no dornase alfa at multiple time points (including one and six months), while evidence for quality-of-life outcomes was limited. Rash and voice change were reported more frequently than with control, and serious adverse effects were not reported in the included trials.[4]

Society and culture

Dornase alfa is an orphan drug.[5]

Research

Dornase alfa has been shown to improve lung function in non-cystic fibrosis pre-term infants atelectasis.[6][7]

Pharmacology

Mechanism of action

Dornase alfa is a recombinant human DNase I that selectively cleaves DNA, by hydrolyzing extracellular DNA in sputum/mucus it reduces mucus viscosity and improves clearance of secretions.[8][4]

Production

The FDA label states that dornase alfa is produced by genetically engineered Chinese hamster ovary (CHO) cells containing DNA encoding the native human DNase I protein.[8]

See also

References

Page Template:Reflist/styles.css has no content.

  1. ^ a b Page Module:Citation/CS1/styles.css has no content."Australian Product Information: Pulmozyme (dornase alfa)". Roche Products Pty Limited. Archived from the original on 12 November 2020.
  2. ^ Page Module:Citation/CS1/styles.css has no content."Pulmozyme Product information". Health Canada. 25 April 2012. Retrieved 9 January 2023.
  3. ^ a b c d e f Page Module:Citation/CS1/styles.css has no content."Pulmozyme- dornase alfa solution". DailyMed. 21 October 2020. Retrieved 9 January 2023.
  4. ^ a b Page Module:Citation/CS1/styles.css has no content.Yang C, Montgomery M (March 2021). "Dornase alfa for cystic fibrosis". The Cochrane Database of Systematic Reviews. 2021 (3) CD001127. doi:10.1002/14651858.CD001127.pub5. PMC 8094421. PMID 33735508.
  5. ^ Page Module:Citation/CS1/styles.css has no content.Collier J (September 1995). "Dornase-alfa and orphan drugs". Lancet. 346 (8975): 633. doi:10.1016/S0140-6736(95)91460-9. PMID 7651014. S2CID 5456247.
  6. ^ Page Module:Citation/CS1/styles.css has no content.Erdeve O, Uras N, Atasay B, Arsan S (April 2007). "Efficacy and safety of nebulized recombinant human DNase as rescue treatment for persistent atelectasis in newborns: case-series". Croatian Medical Journal. 48 (2): 234–239. PMC 2080511. PMID 17436388.
  7. ^ Page Module:Citation/CS1/styles.css has no content.Hendriks T, de Hoog M, Lequin MH, Devos AS, Merkus PJ (August 2005). "DNase and atelectasis in non-cystic fibrosis pediatric patients". Critical Care. 9 (4) R351: R351–R356. doi:10.1186/cc3544. PMC 1269442. PMID 16137347.
  8. ^ a b Page Module:Citation/CS1/styles.css has no content.Pulmozyme (dornase alfa) inhalation solution: US Prescribing Information (FDA label, revised February 2024) (PDF) (Report). U.S. Food and Drug Administration. Retrieved 2025-12-24.

Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Lua error in mw.title.lua at line 404: bad argument #2 to 'title.new' (unrecognized namespace name 'Portal').

Retrieved from "https://cosmopedia.co/index.php?title=Dornase_alfa&oldid=1279838"